MINNEAPOLIS--(BUSINESS WIRE)--Imricor and MiRTLE Medical announce a joint development agreement to fully integrate MiRTLE’s MR compatible 12-lead ECG system with Imricor’s Advantage-MR™ EP Recorder/Stimulator System. This integration, along with Imricor’s MR compatible catheters, will allow physicians to perform complex cardiac ablations, such as for treating ventricular tachycardia and atrial fibrillation, under real-time MRI-guidance.
“This is exciting news,” said Philipp Sommer, MD, electrophysiologist at the Helios Heart Center in Leipzig, Germany. “Ablations to treat complex cardiac arrhythmias could benefit from the use of real-time MR imaging and these arrhythmias require 12-lead ECG monitoring during the procedure. This integration is a critical step towards realizing the full potential of MR-guided electrophysiology.”
Ablations guided by real-time MRI address the fundamental limitations of conventional x-ray guided procedures. Unlike x-ray imaging, MRI allows physicians to visualize soft tissue structures. During MRI-guided ablations, physicians can see the heart and visualize and assess lesion formation to identify inadequate or incomplete ablation lines. These benefits have the potential to make procedures faster, safer, and more effective – all in an environment that is free of ionizing radiation.
ABOUT IMRICOR
Imricor Medical Systems, Inc. is a privately held company committed to unlocking the potential of interventional cardiac magnetic resonance (iCMR) by delivering MR compatible systems and devices that allow physicians to perform cardiac ablations under real-time MRI-guidance.
ABOUT MIRTLE MEDICAL
MiRTLE Medical is a medical device company that designs and manufacturers MRI-compatible 12-lead ECG monitors and software to enable cardiac monitoring inside an MRI to expand clinical and operational procedures to improve patient outcomes.
CAUTION: The Advantage-MR™ EP Recorder/Stimulator System has received CE mark approval; it has not yet been approved for use in the United States. The Vision-MR™ Ablation Catheter has been approved as an investigational device for clinical studies in Europe. All other Imricor products have not yet been approved for use in humans. MiRTLE Medical is not yet approved for use in the United States or Europe. Any use of the product must be under IRB.
